Yet another drugmaker is eliminating therapeutic areas in which R&D is conducted from 14 to 6 areas - oncology, inflamation, neuroscience, vaccines, metabolic disorders and musculoskeletal disorders, a Wyeth spokesman says. Women's health, for example, is being cut. And the number of diseases that Wyeth will attempt to eradicate will dwindle from 55 to 27.
Called Project Impact, the plan is designed to make early-stage research more efficient and will be 'cost neutral,' he adds. About 80 positions will be eliminated, but scientists will have an opportunity to move about. The effort also comes as the approval process before the FDA grows increasingly challenging; Wyeth, in particular, has experienced several setbacks in getting drugs approved.
This is only the latest example in which big pharma is scaling back R&D one way or another. In an effort to cut costs, Pfizer recently disclosed plans to eliminate research into several therapeutic areas and Merck is consolidating research facilities.
4 Comments
This is a trend that has been developing for awhile.
The move is good, as it will allow more companies to properly focus on drugs that have a better chance of success rather than arcane approaches that could cost them a lot of money. A side benefit is, they can take part of the money saved and apply it to a larger project. The pharma/bio business is just that, a business (for profit).
Wyeth filliale française licencie 28%de ses effectifs France : 2 commerciaux sur 3, alors que GSK sort en Février un concurrent du prevenar avec 3 réseaux de forces de vente que va faire Wyeth avec sa cinquantaine de commerciaux face à GSK ? Wyeth filliale française qui licencie 2 commerciaux sur 3 avec des bénéfices toujours plus plus, et un plan social au rabais pour les salariés qui ont donné 20 30 ans de leur vie à Wyeth. Maintenant au tour de la recherche, cela a commencé edans la filliale française. Mais qui est le PDG de cette filliale française ?
Bonjour Michelle,
Je ne comprend pas,
Au revoir,
Ed
que ne comprenez vous pas ?